Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

192 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer.
Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, Chollet P, Llory JF, Letourneau Y, Coudert B, Bertheaut-Cvitkovic F, Larregain-Fournier D, Le Rol A, Walter S, Adam R, Misset JL, Lévi F. Giacchetti S, et al. Among authors: focan c. J Clin Oncol. 2000 Jan;18(1):136-47. doi: 10.1200/JCO.2000.18.1.136. J Clin Oncol. 2000. PMID: 10623704 Clinical Trial.
Sex-dependent least toxic timing of irinotecan combined with chronomodulated chemotherapy for metastatic colorectal cancer: Randomized multicenter EORTC 05011 trial.
Innominato PF, Ballesta A, Huang Q, Focan C, Chollet P, Karaboué A, Giacchetti S, Bouchahda M, Adam R, Garufi C, Lévi FA. Innominato PF, et al. Among authors: focan c. Cancer Med. 2020 Jun;9(12):4148-4159. doi: 10.1002/cam4.3056. Epub 2020 Apr 22. Cancer Med. 2020. PMID: 32319740 Free PMC article. Clinical Trial.
Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group.
Giacchetti S, Bjarnason G, Garufi C, Genet D, Iacobelli S, Tampellini M, Smaaland R, Focan C, Coudert B, Humblet Y, Canon JL, Adenis A, Lo Re G, Carvalho C, Schueller J, Anciaux N, Lentz MA, Baron B, Gorlia T, Lévi F; European Organisation for Research and Treatment of Cancer Chronotherapy Group. Giacchetti S, et al. Among authors: focan c. J Clin Oncol. 2006 Aug 1;24(22):3562-9. doi: 10.1200/JCO.2006.06.1440. J Clin Oncol. 2006. PMID: 16877722 Clinical Trial.
A multicenter evaluation of intensified, ambulatory, chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil, and leucovorin as initial treatment of patients with metastatic colorectal carcinoma. International Organization for Cancer Chronotherapy.
Lévi F, Zidani R, Brienza S, Dogliotti L, Perpoint B, Rotarski M, Letourneau Y, Llory JF, Chollet P, Le Rol A, Focan C. Lévi F, et al. Among authors: focan c. Cancer. 1999 Jun 15;85(12):2532-40. doi: 10.1002/(sici)1097-0142(19990615)85:12<2532::aid-cncr7>3.0.co;2-1. Cancer. 1999. PMID: 10375099 Clinical Trial.
Phase II trial of chronomodulated infusion of high-dose fluorouracil and l-folinic acid in previously untreated patients with metastatic colorectal cancer.
Curé H, Chevalier V, Adenis A, Tubiana-Mathieu N, Niezgodzki G, Kwiatkowski F, Pezet D, Perpoint B, Coudert B, Focan C, Lévi F, Chipponi J, Chollet P. Curé H, et al. Among authors: focan c. J Clin Oncol. 2002 Mar 1;20(5):1175-81. doi: 10.1200/JCO.2002.20.5.1175. J Clin Oncol. 2002. PMID: 11870158 Clinical Trial.
Sex moderates circadian chemotherapy effects on survival of patients with metastatic colorectal cancer: a meta-analysis.
Giacchetti S, Dugué PA, Innominato PF, Bjarnason GA, Focan C, Garufi C, Tumolo S, Coudert B, Iacobelli S, Smaaland R, Tampellini M, Adam R, Moreau T, Lévi F; ARTBC International Chronotherapy Group. Giacchetti S, et al. Among authors: focan c. Ann Oncol. 2012 Dec;23(12):3110-3116. doi: 10.1093/annonc/mds148. Epub 2012 Jun 27. Ann Oncol. 2012. PMID: 22745214 Free article. Clinical Trial.
Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial.
Lévi FA, Zidani R, Vannetzel JM, Perpoint B, Focan C, Faggiuolo R, Chollet P, Garufi C, Itzhaki M, Dogliotti L, et al. Lévi FA, et al. Among authors: focan c. J Natl Cancer Inst. 1994 Nov 2;86(21):1608-17. doi: 10.1093/jnci/86.21.1608. J Natl Cancer Inst. 1994. PMID: 7932825 Clinical Trial.
Efficacy and safety of chronomodulated irinotecan, oxaliplatin, 5-fluorouracil and leucovorin combination as first- or second-line treatment against metastatic colorectal cancer: Results from the International EORTC 05011 Trial.
Innominato PF, Karaboué A, Focan C, Chollet P, Giacchetti S, Bouchahda M, Ulusakarya A, Torsello A, Adam R, Lévi FA, Garufi C. Innominato PF, et al. Among authors: focan c. Int J Cancer. 2021 May 15;148(10):2512-2521. doi: 10.1002/ijc.33422. Epub 2020 Dec 10. Int J Cancer. 2021. PMID: 33270911 Free PMC article.
Implications of circadian clocks for the rhythmic delivery of cancer therapeutics.
Lévi F, Focan C, Karaboué A, de la Valette V, Focan-Henrard D, Baron B, Kreutz F, Giacchetti S. Lévi F, et al. Among authors: focan henrard d, focan c. Adv Drug Deliv Rev. 2007 Aug 31;59(9-10):1015-35. doi: 10.1016/j.addr.2006.11.001. Epub 2007 Jul 4. Adv Drug Deliv Rev. 2007. PMID: 17692427 Review.
192 results